A model qualification method for mechanistic physiological QSP models to support model-informed drug development

CPT: Pharmacometrics and Systems Pharmacology

Volumn 5, Issue 2, 2016, Pages 43-53

  Friedrich, C M ^a  

^a Rosa and Co   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MECHANISM; NONBIOLOGICAL MODEL; PHARMACOLOGY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUANTITATIVE SYSTEMS PHARMACOLOGY; SENSITIVITY ANALYSIS; BIOLOGICAL MODEL; HUMAN; PROCEDURES; SYSTEMS BIOLOGY;

DRUG DISCOVERY; HUMANS; MODELS, BIOLOGICAL; SYSTEMS BIOLOGY;

EID: 84959159927     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.12056     Document Type: Article

References (87)

1. U.S. Food and Drug Administration. Pharmacometrics at FDA. http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/default.htm (2009
2. U.S. Food and Drug Administration. Innovation or stagnation: challenges and opportunity on the critical path to new medical products. http://wwwfdagov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/default.htm (2004
3. Gobburu, J.V. Pharmacometrics 2020. J. Clin. Pharmacol. 50(9 suppl.), 151S-157S (2010
4. Visser, S.A., de Alwis, D.P., Kerbusch, T., Stone, J.A., & Allerheiligen, S.R. Implementation of quantitative and systems pharmacology in large pharma. CPT Pharmacometrics Syst. Pharmacol. 3, e142 (2014
5. Stone, J.A., et al. Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry. J. Clin. Pharmacol. 50(9 suppl.), 20S-30S (2010
6. Lalonde, R.L., et al. Model-based drug development. Clin. Pharmacol. Ther. 82, 21-32 (2007
7. Miller, R., et al. How modeling and simulation have enhanced decision making in new drug development. J. Pharmacokinet. Pharmacodyn. 32, 185-197 (2005
8. Milligan, P.A., et al. Model-based drug development: a rational approach to efficiently accelerate drug development. Clin. Pharmacol. Ther. 93, 502-514 (2013
9. Romero, K., et al. The future is now: model-based clinical trial design for Alzheimer s disease. Clin. Pharmacol. Ther. 97, 210-214 (2015
10. Sorger, P.K., et al. Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms. pp 1-48. An NIH white paper by the QSP Workshop Group (NIH, Bethesda, MD, 2011
11. Zhang, L., Allerheiligen, S.R., Lalonde, R.L., Stanski, D.R., & Pfister, M. Fostering culture and optimizing organizational structure for implementing model-based drug development. J. Clin. Pharmacol. 50(9 Suppl), 146S-150S (2010
12. Alkema, W., Rullmann, T., & van Elsas, A. Target validation in silico: does the virtual patient cure the pharma pipeline?. Expert Opin. Ther. Targets 10, 635-638 (2006
13. Butcher, E.C., Berg, E.L., & Kunkel, E.J. Systems biology in drug discovery. Nat. Biotechnol. 22, 1253-1259 (2004
14. Rajasethupathy, P., Vayttaden, S.J., & Bhalla, U.S. Systems modeling: a pathway to drug discovery. Curr. Opin. Chem. Biol. 9, 400-406 (2005
15. van der Graaf, P.H. CPT: Pharmacometrics and Systems Pharmacology. CPT: Pharmacometrics Syst. Pharmacol. 1, e8 (2012
16. van der Graaf, P.H., & Benson, N. Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharm. Res. 28, 1460-1464 (2011
17. Jusko, W.J. Moving from basic toward systems pharmacodynamic models. J. Pharm. Sci. 102, 2930-2940 (2013
18. Friberg, L.E., & Karlsson, M.O. Mechanistic models for myelosuppression. Invest. New Drugs 21, 183-194 (2003
19. Matsuoka, Y., et al. A comprehensive map of the influenza A virus replication cycle. BMC Syst. Biol. 7, 97 (2013
20. Shipman, M., et al. Proteomic and systems biology analysis of the monocyte response to Coxiella burnetii infection. PLoS One 8, e69558 (2013
21. de Graaf, A.A., et al. Nutritional systems biology modeling: from molecular mechanisms to physiology. PLoS Comput. Biol. 5, e1000554 (2009
22. van Riel, N.A. Dynamic modelling and analysis of biochemical networks: mechanismbased models and model-based experiments. Brief. Bioinform. 7, 364-374 (2006
23. Wolkenhauer, O., et al. SysBioMed report: advancing systems biology for medical applications. IET Syst. Biol. 3, 131-136 (2009
24. Materi, W., & Wishart, D.S. Computational systems biology in drug discovery and development: methods and applications. Drug Discov. Today 12, 295-303 (2007
25. Petrasek, D. Systems biology: the case for a systems science approach to diabetes. J. Diabetes Sci. Technol. 2, 131-134 (2008
26. Kumar, N., Hendriks, B.S., Janes, K.A., de Graaf, D., & Lauffenburger, D.A. Applying computational modeling to drug discovery and development. Drug Discov. Today 11, 806-811 (2006
27. American Diabetes Association Consensus Panel. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 27, 2262-2265 (2004
28. Beard, D.A., Bassingthwaighte, J.B., & Greene, A.S. Computational modeling of physiological systems. Physiol. Genomics 23, 1-3; discussion 4 (2005
29. Beard, D.A., & Kushmerick, M.J. Strong inference for systems biology. PLoS Comput. Biol. 5, e1000459 (2009
30. Csete, M.E., & Doyle, J.C. Reverse engineering of biological complexity. Science 295, 1664-1669 (2002
31. Lazebnik, Y. Can a biologist fix a radio?. Or, what I learned while studying apoptosis. Cancer Cell 2, 179-182 (2002
32. Sheiner, L.B. Learning versus confirming in clinical drug development. Clin. Pharmacol. Ther. 61, 275-291 (1997
33. Rullmann, J.A., Struemper, H., Defranoux, N.A., Ramanujan, S., Meeuwisse, C.M., & van Elsas, A. Systems biology for battling rheumatoid arthritis: application of the Entelos PhysioLab platform. Syst. Biol. (Stevenage) 152, 256-262 (2005
34. Gadkar, K.G., et al. Dosing and timing effects of anti-CD40L therapy: predictions from a mathematical model of type 1 diabetes. Ann. NY Acad. Sci. 1103, 63-68 (2007
35. Kansal, A.R. Modeling approaches to type 2 diabetes. Diabetes Technol. Ther. 6, 39-47 (2004
36. Waters, S.B., Topp, B.G., Siler, S.Q., & Alexander, C.M. Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion. J. Diabetes Sci. Technol. 3, 68-82 (2009
37. Musante, C.J., Lewis, A.K., & Hall, K. Small-And large-scale biosimulation applied to drug discovery and development. Drug Discov. Today 7(20 Suppl), S192-S196 (2002
38. Bartlett, D.W., Friedrich, C., Reed, M., & Baillie, R. Application of a physiologically based model incorporating drug-specific PK modules to support optimization of GLP-1 receptor agonist combination therapies for type 2 diabetes. AAPS. San Antonio, TX http://abstracts.aaps.org/Verify/aaps2013/postersubmissions/T3173.pdf (2013
39. Kumar, R., Geiser, J., Leohr, J., Leishman, D., & Topp, B. Designing optimal basal insulin analogs using a quantitative systems pharmacology model. ACoP. http://www.vantageresearch. net/wp-content/uploads/2015/10/diabetes-Acop-rk.pdf Las Vegas, NV (2014
40. Tess, D., et al. Impact of modeling on GPR119 agonist development. ACoP. http://www.rosaandco.com/posters/rosaACoP2011Pfizerabstract.pdfSan Diego, CA (2011
41. Shoda, L., et al. The type 1 diabetes PhysioLab platform: a validated physiologically based mathematical model of pathogenesis in the non-obese diabetic mouse. Clin. Exp. Immunol. 161, 250-267 (2010
42. Fousteri, G., et al. Virtual optimization of nasal insulin therapy predicts immunization frequency to be crucial for diabetes protection. Diabetes 59, 3148-3158 (2010
43. Meeuwisse, C.M., et al. Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint. Arthritis Rheum. 63, 1265-1273 (2011
44. Young, D.L., & Michelson, S. eds. Systems Biology in Drug Discovery and Development (Hoboken, NJ, Wiley, 2011
45. Yan, L., et al. Quantitative systems pharmacology modeling to evaluate clinical response of an anti-TNFalpha/anti-Ang2 bispecific antibody in rheumatoid arthritis. ASCPT Atlanta, GA. http://www.rosaandco.com/posters/rosaASCPT2014AbstrMedImm.pdf (2014
46. Maxwell, G., & Mackay, C. Application of a systems biology approach to skin allergy risk assessment. Altern. Lab. Anim. 36, 521-556 (2008
47. Westmoreland, C., et al. Assuring safety without animal testing: Unilever s ongoing research programme to deliver novel ways to assure consumer safety. ALTEX 27, 61-65 (2010
48. Bansal, L. A Quantitative Systems Pharmacology (QSP) approach to understand the pathogenesis of acne and evaluate new acne therapies. ACoP. Las Vegas, NV.http://www.rosaandco.com/webinarBansal.html (2014
49. Kang, E.G., et al. Mechanistic and quantitative physiological models for the evaluation and prioritization of dermatology disease targets. ASCPT. Indianapolis, IN. http://www.rosaandco.com/pressReleases/ASCPTPreconferenceProposal2012.pdf 2013
50. Howell, B.A., Siler, S.Q., & Watkins, P.B. Use of a systems model of drug-induced liver injury (DILIsym(VR )) to elucidate the mechanistic differences between acetaminophen and its less-Toxic isomer, AMAP, in mice. Toxicol. Lett. 226, 163-172 (2014
51. Howell, B.A., et al. In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsymTM: a mechanistic, mathematical model of DILI. J. Pharmacokinet. Pharmacodyn. 39, 527-541 (2012
52. Shoda, L.K., Woodhead, J.L., Siler, S.Q., Watkins, P.B., & Howell, B.A. Linking physiology to toxicity using DILIsymVR , a mechanistic mathematical model of drug-induced liver injury. Biopharm. Drug Dispos. 35, 33-49 (2014
53. Woodhead, J.L., et al. An analysis of N-Acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J. Pharmacol. Exp. Ther. 342, 529-540 (2012
54. Woodhead, J.L., et al. Mechanistic modeling reveals the critical knowledge gaps in bile acid-mediated DILI. CPT Pharmacometrics Syst. Pharmacol. 3, e123 (2014
55. Demin, O., et al. Systems pharmacology models can be used to understand complex pharmacokinetic-pharmacodynamic behavior: an example using 5-lipoxygenase inhibitors. CPT Pharmacometrics Syst. Pharmacol. 2, e74 (2013
56. Lewis, A.K., Paterson, T., Leong, C.C., Defranoux, N., Holgate, S.T., & Stokes, C.L. The roles of cells and mediators in a computer model of chronic asthma. Int. Arch. Allergy Immunol. 124, 282-286 (2001
57. Peterson, M.C., & Riggs, M.M. A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling. Bone 46, 49-63 (2010
58. Gadkar, K. QSP-based approaches to predict the clinical impact of different HDLmodifying strategies on reverse cholesterol transport, a critical mechanism for plaque clearance in atherosclerosis. ACoP. Las Vegas, NV. http://www.acop5.org/program (2014
59. Friedrich, C. Mechanistic physiological modeling elucidates in vitro and in vivo PCSK9 effects on LDLR and LDL. ACoP. Las Vegas, NV. http://www.acop5.org/program (2014
60. Kleiman, M., Sagi, Y., Bloch, N., & Agur, Z. Use of virtual patient populations for rescuing discontinued drug candidates and for reducing the number of patients in clinical trials. Altern. Lab. Anim. 37 Suppl 1, 39-45 (2009
61. Schmidt, B.J., et al. Development of a quantitative systems pharmacology platforms to support translational research and clinical development in immuno-oncology. ASCPT. Atlanta, GA. http://www.rosaandco.com/posters/bms-rosa-ImmunoOncologyposter-ASCPT2015.pdf (2014
62. Singh, P., et al. A systems pharmacology model to characterize the effect of blinatumomab in patients with adult B-precursor acute lymphoblastic leukemia (B-ALL). ASCPT. Atlanta, GA. http://www.rosaandco.com/webinarSinghI.html (2014
63. Rieger, T., Tess, D., & Jones, J. Assessment of the therapeutic potential of GLP-11GIP using an integrated model of human metabolism. ACoP. Las Vegas, NV.http://www.acop5.org/program (2014
64. Yuraszeck, T., Zhu, M., & Singh, I. A population-based approach to systems pharmacology (SP) modeling of the effect of blinatumomab in adult B-precursor acute lymphoblastic leukemia patients. ACoP. Las Vegas, NV. http://www.acop5.org/program (2014
65. Moore, K., et al. Use of a large biological model with single-dose clinical data to predict hemoglobin (Hb) response in patients with anemia. ACoP. San Diego, CA.http://www.vantage-research.net/images/anemia-Acop-kmoore.pdf (2011
66. Peterson, M.C., & Riggs, M.M. FDA advisory meeting clinical pharmacology review utilizes a quantitative systems pharmacology (QSP) model: a watershed moment?. CPT Pharmacometrics Syst. Pharmacol. 4, e00020 (2015
67. Kreeger, P.K., & Lauffenburger, D.A. Cancer systems biology: a network modeling perspective. Carcinogenesis 31, 2-8 (2010
68. Friedrich, C.M., & Paterson, T.S. In silico predictions of target clinical efficacy. Drug Discov. Today 3, 216-222 (2004
69. Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 30, 1638-1646 (2007
70. Agoram, B. Evaluating systems pharmacology models is different from evaluating standard pharmacokinetic-pharmacodynamic models. CPT Pharmacometrics Syst. Pharmacol. 3, e101 (2014
71. Friedrich, C.M., Bosley, J., Baillie, R., & Beaver, R. Qualifying mechanistic physiological models for use in pharmaceutical discovery and development. ACoP. San Diego, CA. http://www.rosaandco.com/posters/rosaACoP2011Methodabstract.pdf (2011
72. Brown, K.S., & Sethna, J.P. Statistical mechanical approaches to models with many poorly known parameters. Phys. Rev. E Stat. Nonlin. Soft Matter Phys. 68(2 Pt 1), 021904 (2003
73. Gutenkunst, R.N., Casey, F.P., Waterfall, J.J., Myers, C.R., & Sethna, J.P. Extracting falsifiable predictions from sloppy models. Ann. NY Acad. Sci. 1115, 203-211 (2007
74. Gutenkunst, R.N., Waterfall, J.J., Casey, F.P., Brown, K.S., Myers, C.R., & Sethna, J.P. Universally sloppy parameter sensitivities in systems biology models. PLoS Comput. Biol. 3, 1871-1878 (2007
75. Kohl, M. Standards, databases, and modeling tools in systems biology. Methods Mol. Biol. 696, 413-427 (2011
76. Waterfall, J.J., et al. Sloppy-model universality class and the Vandermonde matrix. Phys. Rev. Lett. 97, 150601 (2006
77. Weisse, A.Y., Middleton, R.H., & Huisinga, W. Quantifying uncertainty, variability and likelihood for ordinary differential equation models. BMC Syst. Biol. 4, 144 (2010
78. Marino, S., Hogue, I.B., Ray, C.J., & Kirschner, D.E. A methodology for performing global uncertainty and sensitivity analysis in systems biology. J. Theor. Biol. 254, 178-196 (2008
79. Kitano, H. Towards a theory of biological robustness. Mol. Syst. Biol. 3, 137 (2007
80. Bangs, A. Predictive biosimulation and virtual patients in pharmaceutical R and D. Stud. Health Technol. Inform. 111, 37-42 (2005
81. Hall, K., Baillie, R., & Michelson, S. Biosimulation: dynamic modeling of biological systems. Ch 27, Vol. 37. (ed. Doherty, A.) Annual Reports in Medicinal Chemistry, 1st Edition. pp 279-288 (Academic Press, New York, NY, 2002
82. Benson, N., et al. Systems pharmacology of the nerve growth factor pathway: use of a systems biology model for the identification of key drug targets using sensitivity analysis and the integration of physiology and pharmacology. Interface Focus 3, 20120071 (2013
83. Holford, N The visual predictive check-superiority to standard diagnostic (Rorschach) plots. http://www.page-meeting.org/page/page2005/PAGE2005P105.pdf (2005
84. Jadhav, P.R., & Gobburu, J.V. A new equivalence based metric for predictive check to qualify mixed-effects models. AAPS J. 7, E523-E531 (2005
85. Friedrich, C.M. Model qualification approaches for quantitative systems pharmacology (QSP) and mechanistic physiological models. ACoP Arlington, VA. http://www.rosaandco.com/posters/rosaACoP2015MQMposter.pdf (2015
86. Sauro, H.M., et al. Next generation simulation tools: the Systems Biology Workbench and BioSPICE integration. OMICS 7, 355-372 (2003
87. Topp, M.S., et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 29, 2493-2498 (2011